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Abstract 
BACKGROUND: Several iron indicators can be used to detect iron deficiency anaemia (IDA) where confounding 
comorbidities occurred such as patients with regular hemodialysis.  
AIM: This study was aimed to determine the diagnostic value of serum transferrin receptor (sTfR) and transferrin 
receptor-transferrin index (TfR-F index) and to combine these two markers in detecting IDA in regular 
hemodialysis anaemic patients.  
METHODS: There were 70 patients recruited consecutively. IDA was diagnosed based on TS < 20% and ferritin 
level < 200 ng/L and functional iron deficiency when TS < 20% and ferritin > 200 ng/L. TfR-F index calculated as 
sTfR/log ferritin.  
RESULTS: Correlation of ferritin to iron level was changed when its correlation adjusted by confounding 
inflammation (CRP level > 10). The correlation strength of ferritin to iron serum before adjusted was r = 0.37 with 
p = 0.02 but became r = 0.65 with p = 0.023 after adjusted to CRP > 10. In inflammation (CRP > 10), ferritin mild-
moderately correlated with iron but became moderately strong when there was no inflammation (CRP < 10). AUC 
for sTfR was 0.77 with p = 0.028 (95% CI 0.55-0.99), and for TfR-F index has larger AUC 0.85% with p = 0.004 
(95%CI 0.69-1.00), hence TfR-F index more superior than sTfR. sTfR and sTfR-F index were not correlated with 
CRP with p > 0.05, and sTfR and TfR-F index mean level was different between IDA and ACD patients although 
not statistically significant.  
CONCLUSION: When sTfR and the TfR-F index used in combination to detect IDA, we found the largest AUC on 
ROC 0.98 (95% CI 0.94-1.00). 
 
 
 
 
 
 
 
 
Introduction 
 
Anaemia is a well-known problem in chronic 
kidney disease (CKD) especially end-stage renal 
disease who need regular hemodialysis (RH) leading 
to higher morbidity and mortality rate. Anaemia affects 
49-55% of patient with CKD and more prevalent once 
diseases become more advanced. Moreover, in the 
population-based survey, anaemia is an essential 
indicator of iron deficiency [1], [2], [3]. Although many 
conditions contributing to anaemia in CKD patients 
such as the diminished production of erythropoietin 
stimulating agent (ESA), blood loss due to bleeding 
disorders and frequent laboratory test, impaired of iron 
absorption and iron retention within reticuloendothelial 
[4], every anaemia should be defined of its original 
causes to be well managed. ESA according to KDOQI 
is one of many important treatment options for 
anaemia in CKD patients, and to achieve a maximal 
response, iron status should be determined. 
Unresponsiveness to ESA treatment is defined when 
iron availability in time for erythropoiesis deficient, 
therefore iron management is an essential element for 
anaemia in CKD patients. There were two major iron 
disorders in this group of patients’ absolute iron 
deficiency and functional iron deficiency. These two 
different iron deficiency (ID) might be hard to 
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distinguish since definitive tools for each of those 
conditions is lacking [5], [6]. 
Several iron indicators can be used to detect 
iron deficiency anaemia (IDA) in a setting where 
confounding comorbidities co-occur such as patients 
with RH. The most available iron indicators for IDA in 
the complicated area are transferrin saturation (TS) 
and ferritin level [4], [7].
 
But these two indicators have 
been known affected by inflammation where 
hemodialysis itself, an inflammation condition through 
uremic toxin, underlying diseases, hemodialysis 
process, making their interpretation hindered by 
physiologic factors and cause failure to detect ID 
status [8], [9]. The best diagnostic tool to identify IDA 
in CKD is still iron stained bone marrow aspiration 
(BMA) but because BMA is invasive, could not be 
used as a standard of care in daily practice. Therefore 
more convenient non-invasive and reliable enough 
method to detect iron status is needed. Recently two 
markers emerged, e.g., soluble transferrin receptor 
(sTfR) and the ratio of sTfR/log ferritin (TfR-F index) 
as a new promising indicator that can differentiate IDA 
with others especially anaemia of chronic disease 
(ACD). These two markers not entirely influenced by 
concurrent chronic disease as well as inflammation 
[4], [10], [11], [12]. 
sTfR is a monomer glycoprotein that detached 
from transmembrane TfR protein after truncated and 
lost their first 100 amino acid then released into the 
blood became sTfR. While TfR-F index is calculated 
from rationing sTfR over logarithm of ferritin, there 
was a close linear relationship between TfR-F index 
and iron store. Their value may be negative in the 
condition where iron is in a deficit state to maintain 
normal haemoglobin level [13]. The Clinical role of 
sTfR in identifying IDA patients has been studied in 
numbers of researches. Majority of these studies 
support the value of sTfR to detect ID and be able to 
differentiate IDA from ACD [14], [15], [16], [17].
 
However, Fussaro et al. showed sTfR was not much 
better than TS or ferritin to detect ID in patients with 
CKD [18]. Data from thalassemia population revealed 
sTfR is a diagnostic tool with moderate accuracy to 
detect IDA patient, as well as in sickle cell anaemia 
sTfR level reflecting more to erythropoietic activity 
than to ID [19], [20]. Punnonen et al. presented that 
TfR-F index has higher sensitivity and specificity to 
distinguish IDA from ACD and this ratio has 
corroborated by several other studies [4], [21], [22]. 
However a recent meta-analysis by Infusino et al. 
claimed that sTfR has better clinical performance than 
TfR-F index in identifying IDA [23]. 
This study aim was to determine the 
diagnostic value of sTfR and TfR-F index and to 
combine these two markers in detecting IDA in RH 
anaemic patients.  
 
 
Material and Methods 
 
This observational cross-sectional study was 
performed to determine the diagnostic value of sTfR 
and TfR-F index to detect IDA in RH anaemic patients 
at Sanglah Hospital Bali. There were 70 patients 
recruited consecutively and agreed to sign an 
informed consent approved by the Institutional Review 
Board of Sanglah hospital by the ethical principles of 
the Declaration of Helsinki. IDA was diagnosis based 
on TS < 20% and ferritin level < 200 ng/L and 
functional ID when TS < 20% but ferritin > 200 ng/L 
[24], [25], [26]. Medical history, physical examination, 
conventional haematology parameters including CBC, 
Iron serum, Total iron binding capacity (TIBC), ferritin 
serum, haemoglobin level, CRP, sTfR were studied. 
sTfR was measured using Biovender Human ELISA 
kit on RD 1940 11100. TfR-F index calculated as 
sTfR/log ferritin [4], [21]. 
Table 1: Characteristics of study subjects 
Characteristics Number (mean or %) 
Gender 
Male 
Female 
 
40 (57.1) 
30 (42.9) 
Age (year), median (min-max) 51 (23-60) 
BMI (kg/m
2
), mean ± SD 21.35 ± 2.14 
Hemoglobin (gram/dl), mean ± SD 7.77 ± 1.24 
MCV (fl), mean ± SD 88.45 ± 6.07 
MCHC (%), mean ± SD 30.41±2.01 
MCH (pg), mean ± SD 27.22±2.58 
RDW (%), mean ± SD 14.65±2.09 
SI (g/dl), median (min-max) 58.67 (11.52-316.80) 
TIBC (g/dl), median (min-max) 175.00 (91.00-701.00) 
Ferritin (ng/ml), median (min-max) 795.65 (24.35-3944.00) 
Transferrin saturation (%), median (min-max) 34.67 (4.93-99.62) 
CRP (mg/L), median (min-max) 24.82 (1.00-92.09) 
sTfR (g/ml), median (min-max) 0.61 (0.16-4.23) 
IDA, n (%) 6 (8.57) 
ACD, n (%) 18 (25.7) 
TfR-F index, median (min-max) 0.28 (0.05-3.05) 
BMI: Body Mass Index; MCV: Mean Corpuscular Volume; MCHC: Mean Corpuscular 
Hemoglobin Concentration; MCH: Mean Corpuscular Hemoglobin; RDW: Red Cell 
Distribution Width; SI: Serum Iron; TIBC: Total Iron Binding Capacity; CRP: C-Reactive 
Protein; sTfR: Soluble Transferrin Receptor; IDA: Iron Deficiency Anemia; ACD: Anemia of 
Chronic Disease; TfR-F index: TfR/log ferritin ratio. 
 
Statistical analysis was performed using 
SPSS software for windows with p-value < 0.5 
indicating statistical significance. ROC (receiver 
operating curve) was performed, and the AUC (area 
under the curve) was calculated to assess the power 
of sTfR and TfR-F index to detect IDA in RH anaemic 
patients. The AUC is a measure of test accuracy, with 
the largest area under curve indicating the better test. 
The optimal cut-off value of sTfR and TfR-F index 
were determined using ROC curve for sensitivity, 
specificity, positive predictive value (PPV), negative 
predictive value (NPV), the accuracy of the test. The 
closer the curve to the upper left corner of the plot the 
more accurate the test was. In this study, the cut-off 
value was selected to the point where sensitivity 
slightly overwhelming specificity by the goal of sTfR 
and TfR-F index to screen more IDA patients. Multiple 
regression analysis was performed to compare the 
AUC area of sTfR, TFR index and when sTfR and 
TfR-F index were combined. Person's correlation 
analysis was also performed to evaluate the possible 
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connections of each parameter especially main iron 
indicators to inflammation marker. 
 
 
Results 
 
Out of 70 patients enrolled in this study, 40 
(57.1%) were male, and 30 (40.2%) were female. A 
total of 6 patients (8.57%) and 18 patients (25.7%) 
were with IDA and ACD, respectively. Characteristics 
of the study subjects are presented in Table 1. 
Correlation of serum ferritin with serum iron is 
depicted in Table 2. It could be seen that the strength 
was altered due to the existence of inflammation 
(CRP). 
Table 2: Partial correlation between serum ferritin and iron 
 CRP < 10 (No Inflammation) CRP < 10 (With Inflammation) 
 Correlation coef p Correlation coef p 
Ferritin 0.648 0.23 0.321 0.016 
CRP: C-Reactive Protein. 
 
In Table 3, no correlation observed between 
new indicators chosen with inflammation (CRP), 
although these new iron indicators (STFR and TFR 
index) differed between IDA and Non-IDA (Table 4). 
However, the difference was not significant (p > 0.05). 
Table 3: Correlation of STFR and TFR index with CRP 
Variable Correlation coef p 
sTfR -0.129 0.287 
TfR-F index -0.76 0.531 
sTfR: Soluble Transferrin Receptor; TfR-F index: TfR/log ferritin ratio. 
 
Our study revealed that AUC (area under 
curve) for sTfR was 0.77 with p = 0.028 (95% CI 0.55-
0.99). The cut-off value, at its maximum sensitivity of 
83.3% and specificity of 67.2%, was 0.71. The TfR-F 
index has larger AUC, which is 0.85, with p = 0.004 
(95% CI 0.69-1.00). 
Table 4: Mean difference between IDA with Non-IDA 
 
IDA 
(n = 6) 
Non-IDA 
(n = 64) 
p 
sTFR -0.0946 0.2368 0.474 
TfR-F index -0.0124 0.6772 0.141 
sTfR: Soluble Transferrin Receptor; TfR-F index: TfR/log ferritin ratio. 
 
The cut-off value, at its best sensitivity of 
83.3% and specificity of 81.2%, was 0.33. The TfR-F 
index was superior compared to sTfR, as seen in 
Figure 1A. When sTfR and TfR-F index were used in 
combination to determine the existence of IDA in 
regular hemodialysis patients (Figure 1B), it was 
found that they carry the largest AUC, which is 0.98 
(95% CI 0.94-1.00). 
 
 
A) 
  
B) 
 
Figure 1: A) The receiver operating curve (ROC) of sTfR and TfR-F 
index to detect IDA in RH patients. B) The receiver operating curve 
(ROC) of sTfR and TfR-F index combination to detect IDA in RH 
patients 
 
 
 
Discussion 
 
CKD is a steady, gradual progressive chronic 
disease where kidney functions finally diminished, and 
this group of patients will mostly require RH with a 
higher mortality rate when compared to the general 
population [27], [28]. Data from 5 European countries 
in DOPP study found that the prevalence of anaemia 
in RH patients was 49% (by the year 1989-1999) – 
55% (by the year 2000) [29]. Among three main type 
of anaemia in CKD population which are decreased 
ESA production due to kidney disorders, anaemia of 
chronic disorder and IDA, IDA in CKD population in 
term of clinical practice posed substantial challenges 
[30]. There was numerous and multifactorial process 
contributed including occult bleeding, chronic 
bleeding, defect in iron absorption because of 
inflammation, frequent laboratory testing, massive 
ESA treatment with supraphysiologic erythropoiesis. 
The annual blood loss estimated to be 1.5-3 gram [1], 
[30]. Besides absolute ID where iron storage is 
severely reduced or absent in bone marrow, however 
patient on RH also have the functional ID that partly 
related to ESA treatment and ACD due to 
inflammatory state of its underlying pathologic [31]. 
This functional ID markedly defines by sufficient iron 
store on body tissue but lack of iron availability for 
erythropoietic processed [5], [6], [32].
 
Our present study found that 6 (8.6%) patient 
with IDA using TS < 20% and ferritin < 200 ng/L, and 
18 (25.7%) with functional ID based on KDOQI, 
Pernefri, and Bahrainwalla et al., [3], [24], [26]. It is 
generally believed that ID should clinically determine 
whether an absolute iron deficiency or functional iron 
deficiency is. However, this separation is often 
practically impossible to delineate. One clue to hold 
that help determined functional ID related to 
inflammation is retrospectively by observing ESA 
treatment responses of intravenous iron with or 
without concomitant raise of ESA dose and decreased 
ferritin level [32]. It is well known that TS and ferritin 
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are not proper iron indicators in the setting of 
inflammation because of the confounding effect of 
immune response to inflammation could 
compromising the true role of TS and ferritin. Ferritin 
is a positive acute phase protein where its level 
increased begin early during inflammation reach its 
peak in a week. From an experimental longitudinal 
study on serum ferritin, reported that ferritin level 
reaches its maximal after 3 days and gradually 
returned to the normal level in the next 10 days [1]. 
The confounding effect of inflammation can mislead 
conclusion whether over or underestimate of ID 
prevalence. According to BRIDA (Biomarkers 
Reflecting Inflammation and Nutrition Determinants of 
Anemia) project to assess the effect of inflammation 
on ferritin level to estimate ID, one should consider 
regression correction factors. The study performed on 
29765 pre-school children and 25731 women of 
reproductive age using CRP and a1-acid glycoprotein 
(AGP) as a marker of inflammation reported that 
regression correction changes the estimated 
prevalence of ID in pre-school by median + 25 
percentage points when ferritin serum was used [33]. 
BRIDA project suggested the need to determine 
marker of inflammation when assessing iron indicators 
status even at the population level [34], e.g., CRP for 
acute inflammation (rapid onset within hours) or AGP 
(late rising in 24 hours and lasted 4-5 days) for 
chronic inflammation [35]. The precise underlying 
pathophysiologic how inflammation influence and 
change iron indicators are yet to be defined. 
Inflammation and iron status (nutrition in a broad 
sense) are well connected in a way bidirectionally 
such that nutrition disorders can compromise immune 
function. Also, inflammation through immune 
response released acute phase protein ferritin and 
also hepcidin in order to withhold iron that certain 
microbe growth desperately depends on [1].
 
Disorder 
of iron metabolism happened because acute phase 
protein ferritin, transferrin, hepcidin have their ability to 
disturb the distribution of iron in every cell of the 
human body. Whether acute inflammation resulted 
from infection or injury, or chronic inflammation 
causes metabolic disturbance through releasing 
cytokines, and this can affect the regulation and 
production of the acute hepatic protein that 
contributed to the disorder of iron metabolism. 
Besides, several studies support the notion that during 
inflammation iron absorption on gastrointestinal also is 
compromised [33], [36].
 
 In this study, we found that the correlation of 
ferritin to iron level was changed when its correlation 
adjusted by confounding inflammation (CRP level > 
10). The correlation strength of ferritin to iron serum 
before adjusted was r = +0.37 with p = 0.02 but 
became r = +0.65 with p = 0.023 after adjusted to 
CRP > 10. In the setting of inflammation (CRP > 10), 
ferritin mild-moderately correlated to iron but became 
moderately strong when there was no inflammation 
(CRP < 10) where ferritin level truly represents tissue 
iron storage. In the future, knowledge about 
inflammation biomarkers should fill the gaps whether 
specific causes of inflammation (e.g., infection, injury, 
arthritis, malignancy, obesity, autoimmune diseases) 
also have their influence on each and specific iron 
indicators status. For example, the liver disease 
where ferritin is produced may directly cause a higher 
level of ferritin without followed by an increased level 
of inflammation biomarkers [33].
 
Using sTfR and TfR-F index to identify IDA in 
RH anaemic patient, we found that our results also 
corroborated several other studies that confirmed 
sTFR and TfR-F index have a significant role to detect 
IDA in the setting of confounding inflammation such 
as regular hemodialysis. We found AUC for sTfR was 
0.77 with p = 0.028 95% CI 0.55-0.99, and for TfR-F 
index has larger AUC 0.85% with p = 0.004 95%CI 
0.69-1.00. A prospective multicenter study to 
differentiate IDA and ACD conducted by Skikne et al., 
using sTfR and TfR-F index, reported that sTfR has 
AUC 0.74% with p < 0.0001 95%CI 0.66-0.83, and 
TfR-F index has larger AUC of 0.87% with p < 0.0001 
hence more superior than sTfR in detecting IDA in the 
setting of inflammation. Bone marrow iron stained as 
golden standard was not used, but established 
opinion and practice for diagnosis and classification of 
anaemia were followed. Another study also found 
sTfR and TfR-F index value are useful parameters in 
assessing iron status in CKD patients. However, they 
were best in complementing to existing indices of 
serum ferritin and TS. TfR-F index also showed more 
superior than sTfR in distinguishing IDA and ACD 
[37]. The study using bone marrow iron staining as the 
golden standard for IDA which only pure no stained 
iron was considered IDA, meanwhile +1 to +6 iron 
staining considered non-IDA [4]. Study on 
inflammatory bowel disease and regular hemodialysis 
on ESA treatment also reported that TfR-F index is 
more accurate at distinguishing between IDA and 
ACD [26], [28], [38], [39]. The superiority of TfR-F 
index over sTfR was not so surprising since this index 
was derived from two elements that reciprocally 
associated (sTfR increased, and ferritin decreased) 
affected by ID. Moreover, especially in RH patients, ID 
was partly related to inflammation status that can 
increase ferritin level [4], [37].
 
TfR-F index has been found to have close, 
linear relationships with stored iron expressed as per 
kg body weight. This finding resulted from the 
experimental study that performs repeated 
phlebotomy of 14 healthy subjects where sTfR and 
ferritin were measured consecutively in serial [22]. A 
longitudinal study of 129 anaemic hospital patients 
observed that TfR-F index increased in IDA but not in 
ACD patient [21]. Peterson et al. reported that TfR-F 
index was decreased in ACD, but increased in IDA 
and patient with mixed IDA and ACD [40]. These 
studies again supported TfR-F index was a useful tool 
to detect IDA in the complicated area [41]. However, a 
recent meta-analysis by Infusino et al. showed that 
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the TfR-F index was no better than sTfR in detecting 
IDA in the presence of confounding condition [23].
 
sTfR is a soluble fragment of membrane-
bound TfR that truncated from nearly all cells mostly 
from erythroblast and reticulocyte, has become easier 
to perform in the past 10 years and can be measured 
quantitatively. It is sensitive to represent iron 
availability during the erythropoietic process in bone 
marrow and other tissue as well as represent tissue 
iron status. sTfR increased in absolute ID and during 
stimulated erythropoietic either post ESA treatment or 
other condition such as thalassemia, sickle cell 
anaemia, hemolytic anaemia. In the situation where 
marrow activity is depressed due to hypoplasia, 
chemotherapy-induced marrow depressed, sTfR 
concentration decreased [10], [17], sTfR level can 
range from 8 times below normal to 20 times above 
the normal level [1]. A study in Pakistan reported sTfR 
in RH patients could differentiate between iron replete 
and iron deplete [42]. sTfR also represent iron 
availability during erythropoiesis activity supported by 
a study of Yin et al., through GEE model, sTfR was 
found significantly associated with the time point when 
hemodialysis was performed, meaning iron availability 
in time for undergoing erythropoietic process making 
sTfR an important marker of erythropoietic [43].
 
Our study also found out sTfR, and the TfR-F 
index was not correlated with CRP with p > 0.05, and 
sTfR and TfR-F index mean level was different 
between the patient with ADB and ACD although not 
statistically significant due to low power (small 
samples size). When sTfR and TfR-F index use in 
combination to detect IDA, we found the largest AUC 
on ROC 0.98 95%Ci 0.94-1.00. These findings also 
other studies claimed that sTfR less influenced by 
inflammation and can be used to determine IDA in the 
situation where inflammation and infection co-exist. 
The limitation of our study was not using iron stained 
bone marrow as a golden standard to determine IDA 
patient due to inconvenience and invasiveness. STFR 
was measured by Biovender Human sTfR ELISA kit 
on RD 194011100, not the one that WHO 
recommended [44]. There is no international 
reference standard exist for sTfR assay. It is 
impossible to compare single threshold value that 
would be accurate for all commercial kits and 
chemical device [14]. Since every available 
commercial kit is method-dependent, and this 
difference may cause by the disparity of TFR 
preparation used as standard and raise antibodies 
[14], [16], [45].
 
In conclusion, this study conclusion was sTfR, 
and TfR-F index proved to be important tools to 
determine IDA in RH anaemic patients and TFR index 
has superior accuracy than sTfR. When sTfR and 
TfR-F index used in combination, their diagnostic 
value reaches the best. 
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